DrugPatentWatch Database Preview
CLINICAL TRIALS PROFILE FOR CAMPTOSAR
Clinical Trials for Camptosar
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00004103 | Combination Chemotherapy Followed by Surgery in Treating Patients With Stomach Cancer | Completed | National Cancer Institute (NCI) | Phase 2 | 1998-07-01 | RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug and combining chemotherapy with surgery may kill more tumor cells. PURPOSE: This phase II trial is studying how well irinotecan and cisplatin followed by surgery, floxuridine, and cisplatin work in treating patients with stomach cancer. |
| NCT00004103 | Combination Chemotherapy Followed by Surgery in Treating Patients With Stomach Cancer | Completed | New York University School of Medicine | Phase 2 | 1998-07-01 | RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug and combining chemotherapy with surgery may kill more tumor cells. PURPOSE: This phase II trial is studying how well irinotecan and cisplatin followed by surgery, floxuridine, and cisplatin work in treating patients with stomach cancer. |
| NCT00004182 | Irinotecan in Treating Patients With Metastatic or Recurrent Breast Cancer | Completed | National Cancer Institute (NCI) | Phase 2 | 1999-10-01 | RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of irinotecan in treating patients who have metastatic or recurrent breast cancer. |
| NCT00004182 | Irinotecan in Treating Patients With Metastatic or Recurrent Breast Cancer | Completed | Northwestern University | Phase 2 | 1999-10-01 | RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of irinotecan in treating patients who have metastatic or recurrent breast cancer. |
| NCT00005626 | Phase II Trial With Correlative Laboratory Studies of Single Agent Irinotecan (Camptosar CPT-11) | Completed | National Cancer Institute (NCI) | Phase 2 | 1998-02-01 | RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of irinotecan in treating patients who have newly diagnosed or relapsed non-Hodgkin's lymphoma or leukemia. |
| NCT00005626 | Phase II Trial With Correlative Laboratory Studies of Single Agent Irinotecan (Camptosar CPT-11) | Completed | Upjohn | Phase 2 | 1998-02-01 | RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of irinotecan in treating patients who have newly diagnosed or relapsed non-Hodgkin's lymphoma or leukemia. |
| NCT00005626 | Phase II Trial With Correlative Laboratory Studies of Single Agent Irinotecan (Camptosar CPT-11) | Completed | H. Lee Moffitt Cancer Center and Research Institute | Phase 2 | 1998-02-01 | RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of irinotecan in treating patients who have newly diagnosed or relapsed non-Hodgkin's lymphoma or leukemia. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Camptosar
Condition Name
Condition MeSH
Clinical Trial Locations for Camptosar
Trials by Country
Clinical Trial Progress for Camptosar
Clinical Trial Phase
Clinical Trial Sponsors for Camptosar
Sponsor Name
